Joannes A. Reijers
Leiden, ZH 2333ZA, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Fluctuations in Pharmacokinetics Profiles of Monoclonal Antibodies.
Journal: European journal of drug metabolism and pharmacokinetics
Published: February 28, 2019
Adverse immunostimulation caused by impurities: The dark side of biopharmaceuticals.
Journal: British journal of clinical pharmacology
Published: October 29, 2018
Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: September 13, 2017
MDCO-216 Does Not Induce Adverse Immunostimulation, in Contrast to Its Predecessor ETC-216.
Journal: Cardiovascular drugs and therapy
Published: August 28, 2017
Potential Influence of Endothelial Adsorption on the Delayed Time to Maximum Concentration of Biopharmaceuticals.
Journal: European journal of drug metabolism and pharmacokinetics
Published: August 11, 2017
Remarkable Pharmacokinetics of Monoclonal Antibodies: A Quest for an Explanation.
Journal: Clinical pharmacokinetics
Published: December 22, 2016
Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS.
Journal: Clinical pharmacology and therapeutics
Published: June 30, 2016
Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies.
Journal: European journal of clinical pharmacology
Published: May 07, 2016
A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease.
Journal: European heart journal. Cardiovascular pharmacotherapy
Published: September 17, 2015
Last Updated: 09/26/2026